Literature DB >> 23430668

Association between low red blood cell 5-methyltetrahydrofolate and hyperhomocysteinaemia with hypertension : a cross-sectional study.

Jamal Golbahar1, Esmael Mostafavi.   

Abstract

BACKGROUND: Hyperhomocysteinaemia and other risk factors associated with blood pressure have been reported in large community-based studies in different populations. However, it is not fully established whether hypertension is associated with high plasma total homocysteine levels (tHcy) or components of the homocysteine re-methylation pathway including vitamin B(12), plasma 5-methyltetrahydrofolate (5-MTHF) or red blood cell (RBC) 5-MTHF. AIM: In this study we tested the hypothesis that RBC 5-MTHF could be a marker for long-term folate status in the blood and low RBC 5-MTHF may be associated with hypertension.
METHODS: This was a cross-sectional study in a community-based setting and 492 males and 431 females were investigated. Systolic and diastolic blood pressures were determined and fasting blood samples were taken for determination of plasma tHcy, creatinine, uric acid, lipids, plasma 5-MTHF, RBC 5-MTHF and vitamin B(12).
RESULTS: In males, the risk of hypertension was significantly (95% CI 1.9, 8.7; p = 0.003) increased by 1.8-fold in the first quartile compared with the highest quartile of RBC 5-MTHF when adjusted for body mass index (BMI), age, dyslipidaemia, uric acid, creatinine, smoking, plasma tHcy and vitamin B(12). The risk of hypertension was also significantly increased (95% CI 1.1, 9.2; p = 0.03) by 1.1-fold in the highest quartile compared with the lowest quartile of plasma tHcy when adjusted for BMI, age, dyslipidaemia, uric acid, creatinine, smoking, plasma and RBC 5-MTHF and vitamin B(12). There were no associations of hypertension with plasma tHcy, and other components of the Hcy re-methylation pathway were observed in females.
CONCLUSIONS: The association between hypertension and low RBC 5-MTHF was stronger than any other components of the homocysteine re-methylation pathway. Results from this study suggest that folate measurements in RBC seem to be the most reliable marker indicating 5-MTHF deficiency and disturbances in the Hcy re-methylation pathway in association with hypertension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430668     DOI: 10.1007/BF03297635

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  33 in total

Review 1.  Homocysteine and cardiovascular disease.

Authors:  Dinesh K Kalra
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

2.  Plasma homocysteine concentration and blood pressure in healthy Iranian adults: the Tehran Homocysteine Survey (2003-2004).

Authors:  H Fakhrzadeh; S Ghotbi; R Pourebrahim; R Heshmat; M Nouri; A Shafaee; B Larijani
Journal:  J Hum Hypertens       Date:  2005-11       Impact factor: 3.012

3.  A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage.

Authors:  G Y Lip; E Edmunds; S C Martin; A F Jones; A D Blann; D G Beevers
Journal:  Am J Hypertens       Date:  2001-07       Impact factor: 2.689

4.  Folic acid fortification increases red blood cell folate concentrations in the Framingham study.

Authors:  S F Choumenkovitch; P F Jacques; M R Nadeau; P W Wilson; I H Rosenberg; J Selhub
Journal:  J Nutr       Date:  2001-12       Impact factor: 4.798

5.  Homocysteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features.

Authors:  P Mercié; O Garnier; L Lascoste; M Renard; C Closse; F Durrieu; G Marit; R M Boisseau; F Belloc
Journal:  Apoptosis       Date:  2000-11       Impact factor: 4.677

6.  Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone.

Authors:  Mohsen Kerkeni; Mehdi Tnani; Laurence Chuniaud; Abdelhedi Miled; Khira Maaroufi; François Trivin
Journal:  Mol Cell Biochem       Date:  2006-05-19       Impact factor: 3.396

7.  The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.

Authors:  Salah Kassab; Taysir Garadah; Marwan Abu-Hijleh; Jamal Golbahar; Solomon Senok; Javed Wazir; Khalid Gumaa
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2006-12       Impact factor: 1.636

Review 8.  Folate, homocysteine, endothelial function and cardiovascular disease.

Authors:  Stuart J Moat; Derek Lang; Ian F W McDowell; Zoe L Clarke; Anil K Madhavan; Malcolm J Lewis; Jonathan Goodfellow
Journal:  J Nutr Biochem       Date:  2004-02       Impact factor: 6.048

Review 9.  Clinical usefulness of plasma homocysteine in vascular disease.

Authors:  Graeme J Hankey; John W Eikelboom; Wai Khoon Ho; Frank M van Bockxmeer
Journal:  Med J Aust       Date:  2004-09-20       Impact factor: 7.738

Review 10.  Homocysteine and essential hypertension.

Authors:  Ramón Rodrigo; Walter Passalacqua; Julia Araya; Myriam Orellana; Gonzalo Rivera
Journal:  J Clin Pharmacol       Date:  2003-12       Impact factor: 3.126

View more
  2 in total

Review 1.  A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia.

Authors:  Wen-Wen Wang; Xin-Shi Wang; Zeng-Rui Zhang; Jin-Cai He; Cheng-Long Xie
Journal:  Front Pharmacol       Date:  2017-08-31       Impact factor: 5.810

2.  Associations of plasma homocysteine levels with peripheral systolic blood pressure and noninvasive central systolic blood pressure in a community-based Chinese population.

Authors:  Mohetaboer Momin; Fangfang Fan; Jianping Li; Xianhui Qin; Jia Jia; Litong Qi; Yan Zhang; Yong Huo
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.